Reigetsu Yoshikawa
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Journal: Liver cancer
Published: February 08, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Journal: JHEP reports : innovation in hepatology
Published: August 07, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: December 24, 2019
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Journal: Journal of gastroenterology
Published: October 20, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Journal: JAMA network open
Published: August 03, 2019
Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: March 28, 2017
Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
Journal: Japanese journal of clinical oncology
Published: April 06, 2016
Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma.
Journal: Molecular and clinical oncology
Published: November 19, 2012
Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
Journal: Oncology reports
Published: March 03, 2012
The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy.
Journal: BMC cancer
Published: February 28, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026